DRW Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

DRW Securities’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-9,900	Closed	-$865K	–	535
2024 Q1	$865K	Buy	+9,900	New	+$886K	0.02%	188

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

DRW Securities's BMRN Position: Q2 2026 in Review

DRW Securities sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 12,426 shares — an estimated $702K sold.

DRW Securities first reported a position in BMRN in Q1 2024 and held it in 5 quarters. The position peaked at $702K in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

DRW Securities reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
DRW Securities sold 12,426 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $702K.
DRW Securities first reported a position in BioMarin Pharmaceuticals in Q1 2024 and held it in 5 quarters.
DRW Securities's BioMarin Pharmaceuticals position peaked at $702K in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.